Want to see HK:3759 full AI Analyst Report?
3759 Stock Chart & Stats
HK$24.14
HK$0.24(1.88%)
At close: 4:00 PM EST
HK$24.14
HK$0.24(1.88%)
Day’s Range― - ―
52-Week RangeHK$14.45 - HK$34.86
Previous CloseN/A
Volume1.90M
Average Volume (3M)9.70M
Market Cap
HK$84.30B
Enterprise ValueHK$39.54K
Total Cash (Recent Filing)HK$2.45B
Total Debt (Recent Filing)HK$6.95B
Price to Earnings (P/E)44.6
Beta1.93
Next Earnings
Oct 22, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend Yield0.78%
Share Statistics
EPS (TTM)0.96
Shares Outstanding359,977,870
10 Day Avg. Volume5,676,043
30 Day Avg. Volume9,695,257
Financial Highlights & Ratios
PEG Ratio-2.70
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$37.76Price Target Upside56.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.26
Revenue Forecast (FY)HK$19.45B
Bulls Say, Bears Say
Bulls Say
End-to-end CRDMO PlatformThe integrated CRDMO model covers multiple stages of the drug lifecycle, allowing Pharmaron to support customers beyond a single project type. This broad service scope can deepen relationships, enable cross-selling, and make the company a more embedded long-term outsourcing partner.
Durable Profitability And GrowthPharmaron continues to generate substantial revenue and profit while extending a multi-year growth trend. Although recent growth has moderated, the still-healthy margins and ~1.71B TTM net income provide an earnings base that can fund operations and support continued participation in pharmaceutical outsourcing demand.
Reasonable Capital BaseThe company has a sizeable equity cushion relative to its asset base and moderate TTM leverage, supporting financial resilience compared with a highly levered operating model. This balance-sheet foundation gives Pharmaron capacity to maintain its platform and pursue growth, even though debt has recently increased.
Bears Say
Weak Cash ConversionProfit is not translating efficiently into available cash, as operating cash flow covers only about one-third of net income and free cash flow is nearly negligible. Persistent reinvestment or working-capital drag could constrain internally funded expansion and reduce flexibility during weaker demand periods.
Slowing Growth And Margin PressureThe moderation in revenue growth and decline in margins versus 2021–2024 indicate that the business has less earnings momentum and cushion than in earlier periods. If this steadier trajectory persists, Pharmaron may have less operating leverage to offset costs or sustain historical profit expansion.
Rising Debt Reduces FlexibilityAlthough leverage remains moderate on a TTM basis, the sharp recent increase in debt raises fixed financial obligations and sensitivity to refinancing conditions. Combined with weak free cash flow, higher borrowings could limit capital allocation flexibility and make future investment more dependent on operating improvement.
Pharmaron Beijing Co., Ltd. Class H News
3759 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was HK$14.45 and its highest was HK$34.86 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is HK$84.30B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Oct 22, 2026 which is in 31 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Aug 20, 2026. The company reported HK$0.268 earnings per share for the quarter, missing the consensus estimate of HK$0.278 by -HK$0.01.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Undervalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H pays a Annually dividend of HK$0.23 which represents an annual dividend yield of 0.78%. See more information on Pharmaron Beijing Co., Ltd. Class H dividends here
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.35.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of HK$0.268 in its last earnings report, missing expectations of HK$0.278. Following the earnings report the stock price went up 7.697%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3759
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$37.76 (56.43% Upside)
HK$37.76 (56.43% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.97%
12-Months-Change
Fundamentals
Return on Equity
0.78%
Trailing 12-Months
Asset Growth
24.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
3759 Stock 12 Month Forecast
Average Price Target
HK$37.76
▲(56.43% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―